Liraglutide in Children and Adolescents with Type 2 Diabetes

Published: The New England Journal of Medicine
Date:
Authors: William V Tamborlane, Margarita Barrientos-Pérez, Udi Fainberg, Helle Frimer-Larsen, Mona Hafez, Paula M Hale, Muhammad Y Jalaludin, Margarita Kovarenko, Ingrid Libman, Jane L Lynch, Paturi Rao, Naim Shehadeh, Serap Turan, Daniel Weghuber, Timothy Barrett, Ellipse Trial Investigators
Abstract:
Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Published: The New England Journal of Medicine
Date:
Authors: Vlado Perkovic 1 , Meg J Jardine 1 , Bruce Neal 1 , Severine Bompoint 1 , Hiddo J L Heerspink 1 , David M Charytan 1 , Robert Edwards 1 , Rajiv Agarwal 1 , George Bakris 1 , Scott Bull 1 , Christopher P Cannon 1 , George Capuano 1 , Pei-Ling Chu 1 , Dick de Zeeuw 1 , Tom Greene 1 , Adeera Levin 1 , Carol Pollock 1 , David C Wheeler 1 , Yshai Yavin 1 , Hong Zhang 1 , Bernard Zinman 1 , Gary Meininger 1 , Barry M Brenner 1 , Kenneth W Mahaffey 1 , CREDENCE Trial Investigators
Abstract:
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.

Factors Affecting Hemoglobin A1C in the Diagnosis of Diabetes and Prediabetes in Youth

Published: Journal of Pediatric Nursing
Date:
Authors: Jennifer McGuire Hitt 1 , Pedro Velasquez-Mieyer 2 , Claudia Neira 2 , Patricia Cowan 3
Abstract:
We sought to examine the correlation between variables and A1C levels to determine if prediction modeling could be used in the screening and diagnosis of diabetes and prediabetes in youth. We also sought to test relationships between A1C levels to insulin sensitivity indices and β-cell function indices. Design and methods: We performed a retrospective review of 904 medical records from youth deemed at-risk for the disease.

Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants

Published: The Lancet Diabetes & Endocrinology
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
Diabetes has been defined on the basis of different biomarkers, including fasting plasma glucose (FPG), 2-h plasma glucose in an oral glucose tolerance test (2hOGTT), and HbA1c. We assessed the effect of different diagnostic definitions on both the population prevalence of diabetes and the classification of previously undiagnosed individuals as having diabetes versus not having diabetes in a pooled analysis of data from population-based health examination surveys in different regions.

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Published: The Lancet
Date:
Authors: Richard M Bergenstal 1, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter, DURATION-2 Study Group
Abstract:
Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the thiazolidinedione, pioglitazone, in patients treated with metformin.

Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus

Published: Expert Opin Pharmacother
Date:
Authors: Pedro A Velásquez-Mieyer 1 , Claudia P Neira
Abstract:
Type 1 diabetes mellitus is associated with acute and long-term complications, to which pre- and postprandial hyperglycemia are independent contributors. The objective of this review was to evaluate evidence-based information using biphasic insulin aspart 30 in the treatment of type 1 diabetes mellitus.

Obesity, leptin resistance, and the effects of insulin reduction

Published: International journal of obesity and related metabolic disorders
Date:
Authors: R H Lustig 1 , S Sen, J E Soberman, P A Velasquez-Mieyer
Abstract:
Leptin resistance is a hallmark of obesity, but its etiology is unknown, and its clinical measurement is elusive. Leptin-sensitive subjects have normal resting energy expenditure (REE) at a low leptin concentration, while leptin-resistant subjects have a normal REE at a higher leptin concentration; thus, the ratio of REE:Leptin may provide a surrogate index of leptin sensitivity.

Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist

Published: The Journal of Pediatrics
Date:
Authors: R H Lustig 1 , S R Rose, G A Burghen, P Velasquez-Mieyer, D C Broome, K Smith, H Li, M M Hudson, R L Heideman, L E Kun
Abstract:
Hypothalamic obesity is a rare sequela of cranial insult, for which pathogenesis and treatment remain obscure. In rodents ventromedial hypothalamic damage causes hyperphagia, obesity, hyperinsulinism, and insulin resistance. Reduction of insulin secretion in humans may attenuate weight gain.